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Background: Nuclear factor-κB (NF-κB) plays an important role in the inflammatory response after intracerebral
hemorrhage (ICH). We therefore proposed that NF-κB activation in perihematomal brain tissue might correlate with
clinical outcome in patients with ICH. To confirm this, we studied clinical data of 45 patients with ICH and NF-κB
activation in perihematomal brain tissue and analyzed predictors of clinical outcome as well as the predictive value
of NF-κB activation.
Methods: Forty-five patients with spontaneous basal ganglia hemorrhage were prospectively investigated. The
clinical data were collected, which include demographics, alcohol and tobacco abuse, stroke risk factors,
neuroimaging variables at presentation, Glasgow Coma Scale (GCS) at admission, number of days in hospital,
mechanical ventilation, pneumonia, and outcome. Clinical outcome was assessed by the modified Rankin
Scale at 6 months after ICH. Perihematomal brain tissue was collected, and NF-κB activation was detected
using immunohistochemistry. Univariate analysis and multivariate logistic regression analysis were performed
to determine predictors of the poor outcome.
Results: Immunohistochemical detection showed that NF-κB p65 was expressed in the nuclei of neurons and
glial cells in all patients. The number of nuclear NF-κB p65-positive cells was 54 ± 21. Six months after ICH,
18 (40%) patients achieved a favorable functional outcome (mRS ≤ 3) while 27 (60%) had a poor functional
outcome (mRS 4 to 6). In univariate analysis, predictors of poor functional outcome were lower GCS score on
admission (P = 0.004), larger hematoma volume (P = 0.004), intraventricular extension (P = 0.047), midline shift
(P = 0.005), NF-κB activation (P < 0.0001), mechanical ventilation (P = 0.018), and co-morbidity with pneumonia
(P = 0.002). In multivariate logistic regression analysis, NF-κB activation was the only independent predictor of
poor outcome at 6 months after ICH.
Conclusions: NF-κB activation is closely related to clinical outcome 6 months after ICH in humans. Therefore,
it could be useful to predict prognosis of ICH accurately and should be further evaluated as a target for
therapeutic strategies of ICH in the future.
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Primary intracerebral hemorrhage (ICH) is still a fre-
quent form of cerebrovascular diseases despite improved
control of hypertension. It accounts for 30% of all cases
of stroke in China, approximately twice higher than that
in the West, and is one of the leading causes of stroke-
related mortality and morbidity worldwide [1-3]. Func-
tional outcome in survivors is also poor with fewer than
20% being independent at 6 months [4]. Previous studies
have shown that the prognosis of patients with ICH is
affected by series of factors, such as age, high blood pres-
sure, hematoma volume, Glasgow Coma Scale (GCS)
score on admission, stroke risk factors, underlying disease,
leukocyte counts, neuroimaging, operation, complications,
and so on [5-11], so it is always difficult for us to predict
the outcome accurately.
A series of pathophysiological changes in brain tissue
arises after ICH [12]. Previous studies revealed that a large
number of inflammatory cells surround the hematoma in
the rat model of ICH and that the inflammatory response
is an important mechanism of secondary brain damage
after ICH [13,14]. Nuclear factor-κB (NF-κB) has been
recognized as a critical regulator of inflammatory re-
sponses since its discovery [15]. In unstimulated cells, in-
active NF-κB is sequestered in the cytoplasm by inhibitory
protein IκB. NF-κB can be activated by a wide array of fac-
tors such as thrombin, tumor necrosis factor-α (TNF-α),
interleukin-1 (IL-1), oxidative stress, and growth factors
[16]. Then, the free NF-κB rapidly migrates into the nu-
cleus, binds to DNA, and promotes the transcription of
genes for the release of inflammatory substances. So
NF-κB plays an important role in the inflammatory re-
sponse after ICH [17].
Given the important role played by NF-κB in the sec-
ondary brain damage after ICH, we imagine that NF-κB
activation in perihematomal brain tissue was closely re-
lated to the clinical outcome of patients with ICH. In
other words, NF-κB could be used to predict the clinical
outcome. In order to confirm this, we collected 45 pa-
tients with basal ganglia hemorrhage, studied the clinical
data and perihematomal brain tissue, and analyzed the
predictors of the clinical outcome as well as the predict-
ing value of NF-κB activation.
Materials and methods
Study population
All patients with spontaneous basal ganglia hemorrhage
admitted to the Emergency Neurosurgery Department of
Shandong University Qilu Hospital from October 2011
to August 2013 were screened for this study. Inclusion
criteria were time from symptom onset to specimen col-
lection 6 to 12 h, hematoma volume 30 to 90 ml, and
hematoma evacuation operation conducted along the non-
functional cortex. The intracerebral hemorrhage volumewas measured using the ABC/2 method according to the
CT scanning [18]. Exclusion criteria were rebleeding, sec-
ondary ICH (such as head trauma, aneurysm, vascular
malformation, hemorrhagic infarction, cerebral vein and
sinus thrombosis, tumor, anticoagulant, blood thinners, or
coagulopathy-related hemorrhage), history that may affect
the study (such as bleeding, inflammation, trauma, sur-
gery), use of drugs that affect the immune system (ibupro-
fen, hormones, illicit drug, cocaine or other stimulants,
and so on), presence of underlying diseases within the pre-
vious month, or refusal of participation.
Ethics approval
The study protocol was approved by the Ethics Committee
of Qilu Hospital. All patients’ families received a compre-
hensive description of the study and gave written informed
consent for their relatives’ participation. The specimen for
the study was waste brain tissue discarded during surgery,
and the collection process did not cause any additional
damage to the patient.
Clinical data and specimen collection
Clinical data of patients were collected on admission or
during hospitalization. The variables include demograph-
ics (age and gender), alcohol and tobacco abuse, a detailed
history of stroke risk factors (hypertension, diabetes mel-
litus, coronary heart disease, and chronic obstructive
pulmonary diseases (COPD)), neuroimaging variables at
presentation (hematoma volume, intraventricular exten-
sion, midline shift, hydrocephalus, brain edema), GCS on
admission, number of days in hospital, mechanical ventila-
tion, pneumonia, and outcome. The midline shift was de-
termined by the distance between midline and septum
pellucidum according to the CT scanning.
The proximity to the ICH is a key factor in the inflam-
matory response. Therefore, the specimen (no less than
0.5 cm3 per patient) was collected according to the stand-
ard that the distance between specimen and hematoma
was 1 cm. In order to reduce the traction injury to the ad-
jacent brain tissue, cortical fistula was made according to
the ICH location during operation. Specimen was col-
lected in this process by the same surgeon, and the dis-
tance between specimen and hematoma can be measured
directly. So the samples were collected in the same way
each time. The brain tissue was quickly fixed with 10%
formalin and embedded in wax for immunohistochemistry
(IHC) detection of NF-κB activation.
Detection of NF-κB activation
The activation of NF-κB was detected by IHC. The tissue
sections (4 μm thick) were dewaxed, rehydrated, rinsed
with distilled water and phosphate-buffered saline (PBS),
repaired with EDTA, quenched with 3% H2O2, exposed to
primary antibody (anti-NF-κB p65 antibody, B7162 rabbit
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Sections were then washed with PBS, incubated in poly-
mer helper for 25 min at room temperature, washed again,
and incubated with non-biotin rabbit hypersensitivity two-
step secondary antibody (PV-9001, GBI, USA) for 25 min
at room temperature. Finally, the sections were stained
with diaminobenzidine-H2O2 solution, washed, dehydrated
in graded ethanol, immersed in xylene, and covered with
a coverslip. In order to identify the cell type of nucleus
NF-κB positive cells (neurons or glial cells), double-
labeled IHC was performed on all of the 45 speci-
mens, using the primary antibody (anti-NF-κB p65
antibody, B7162 rabbit polyclonal, ANBO, USA; anti-GFAP
antibody, TA500336 mouse monoclonal, ZSGB-BIO, CHN;
anti-NSE antibody, ZM-0203 mouse monoclonal, ZSGB-
BIO, CHN) and double staining kit (DS-0005, ZSGB-BIO,
CHN). The double-labeled IHC was performed according
to the instructions of the double staining kit.
The slices were observed under the multi-head micro-
scope by five professors of pathology in a blinded fashion.
A total of five no-repeat fields (×400 high magnification)
were randomly selected, the nucleus NF-κB positive cells
were identified, and the numbers of positive cells in the five
fields were added up as the result. The numbers of positive
cells recorded by the five pathologists were consistent.
Functional outcome assessment
Clinical outcome was assessed by modified Rankin Scale
(mRS) at 6 months after ICH. The follow-up was made by
telephone interview or face-to-face assessment. In this
study, the patients were relatively serious due to the
hematoma volume, and three points can be considered as
a good prognosis. Therefore, poor clinical outcome was
defined as mRS ≥ 4 assessed at the 6-month follow-up.
Statistical analysis
The normally and non-normally distributed continuous
variables were expressed as mean ± standard derivation
and median (IQR), respectively. In univariate analysis,
normally distributed continuous variables were analyzed
with Student’s t-test, non-normally distributed continu-
ous variables were analyzed with Mann–Whitney U test,
and categorical variables were analyzed with chi-square
test. Stepwise forward logistic regression was used to de-
termine independent predictors for poor functional out-
come at 6 months after ICH. All tests were two-tailed,
and statistical significance was determined at α level of
0.05. Statistical analysis and charting were performed
using SPSS 19.0 and Excel 2003.
Results
Clinical data and NF-κB activation
The clinical data and NF-κB activation are listed in
Table 1. The number of patients with 30 to 90 ml basalganglia ICH was 419 in total, and 92 (22.0%) refused sur-
gery because of serious underlying disease or some other
personal reasons (such as economic reasons and so on).
All of the others (327, 78.0%) were treated with surgery
in our department. Among patients with an ICH size of
30 to 90 ml that underwent surgical decompression, a
total of 45 patients met our study’s inclusion criteria,
with an age of 53.87 ± 10.78 years (range 35 to 77 years),
29 males and 16 females. Thirty-seven (82.2%) had one
or more underlying diseases: 26 (57.8%) had hyperten-
sion, 11 (24.4%) diabetes mellitus, 5 (11.1%) COPD, and
11 (24.4%) coronary artery diseases. Fourteen (31.1%)
were smokers, and 11 (24.4%) were drinkers. The GCS
score on admission was 5 to 13.
CT scan was performed on all of the 45 patients. The
intracerebral hematoma volume was 59.44 ± 14.26 ml.
Eighteen (40.0%) had intraventricular extension, 10 (22.2%)
had acute hydrocephalus, 13 (28.9%) had perihematoma
brain edema, and 24 (53.3%) had midline shift ≥1 cm.
Hematoma evacuation operation was performed on all
patients along the non-functional cortex, while ventricu-
lar drainage was performed on 16 (35.6%) and craniect-
omy on 12 (26.7%). Mechanical ventilation was required
in 14 (31.1%) patients, and pneumonia was diagnosed in
20 (44.4%) patients. The body temperature was con-
trolled between 36.0°C and 37.0°C with the help of drugs
or physical cooling. Osmotherapy (mannitol or hyper-
tonic saline) was used pre- or post-operation. Mannitol
was used according to the clinical manifestations and
imaging. Serum sodium was maintained at 145 mmol/l
or higher if necessary. The numbers of days in hospital were
18.29 ± 6.89. Do-not-attempt resuscitation or withdrawal-of-
care did not exist in all of the 45 patients.
Immunohistochemical detection showed that NF-κB
p65 was expressed in the nucleus of cells in all of the 45
patients (Figure 1), suggesting that NF-κB was activated
and migrated into the nucleus. Double-labeled IHC
showed that NF-κB p65 was expressed in the nucleus of
both neurons and glial cells (Figure 1). The numbers of
nucleus NF-κB p65-positive cells ranged from 9 to 95,
and the total number was 54.38 ± 20.97.
The numbers of patients mRS scored 0 to 6 at 6 months
after ICH were 0, 3 (6.5%), 8 (17.4%), 7 (15.2%), 9 (19.6%),
16 (34.8%), and 2 (4.3%); thus, 18 (40.0%) patients
achieved a favorable functional outcome (mRS ≤ 3) while
27 (60.0%) had a poor functional outcome (mRS 4 to 6).
Predictors of poor outcome at 6 months after ICH
In univariate analysis of the 6-month outcome, predictors
of poor functional outcome were lower GCS score on ad-
mission (P = 0.004), larger hematoma volume (P = 0.004),
intraventricular extension (P = 0.047), midline shift (P =
0.005), and NF-κB activation (P < 0.0001). In addition, sig-
nificantly more patients with poor outcome needed
Table 1 Predictive value of the characteristics on univariate analysis
Characteristics Total (n = 45) Good outcome (n = 18) Poor outcome (n = 27) Odds ratio (95% CI) P value
Demographics
Male sex 29 (64.4) 10 (55.6) 19 (70.4) 1.900 (0.548 to 6.590) 0.309a
Age, years 53.87 ± 10.78 51.50 ± 10.40 55.44 ± 10.93 0.233b
GCS score on admission 9 (4) 11 (3.5) 9 (2) 0.004c
Risk factors
Smoking 14 (31.1) 5 (27.8) 9 (33.3) 1.300 (0.352 to 4.796) 0.693a
Alcohol abuse 11 (24.4) 5 (27.8) 6 (22.2) 0.743 (0.188 to 2.934) 0.671a
Hypertension 26 (57.8) 10 (55.6) 16 (59.3) 1.164 (0.348 to 3.885) 0.805a
Diabetes mellitus 11 (24.4) 4 (22.2) 8 (29.6) 1.474 (0.369 to 5.885) 0.582a
Coronary heart disease 11 (24.4) 3 (16.7) 8 (29.6) 2.105 (0.475 to 9.338) 0.322a
COPD 5 (11.1) 1 (5.6) 4 (14.8) 2.957 (0.303 to 28.882) 0.333a
Radiologic variables
Hematoma volume, ml 59.44 ± 14.26 52.17 ± 13.10 64.30 ± 13.06 0.004b
Intraventricular extension 18 (40.0) 4 (22.2) 14 (51.9) 3.769 (0.984 to 14.443) 0.047a
Hydrocephalus 10 (22.2) 2 (11.1) 8 (29.6) 3.368 (0.624 to 18.185) 0.143a
Midline shift ≥1 cm 24 (53.3) 5 (27.8) 19 (70.4) 6.175 (1.647 to 23.148) 0.005a
Brain edema 13 (28.9) 3 (16.7) 10 (37.0) 2.941 (0.680 to 12.730) 0.140a
Hospitalizations
Mechanical ventilation 14 (31.1) 2 (11.1) 12 (44.4) 6.400 (1.224 to 33.482) 0.018a
Pneumonia 20 (44.4) 3 (16.7) 17 (63.0) 8.500 (1.964 to 36.790) 0.002a
NF-κB activation 54.38 ± 20.97 37.11 ± 16.51 65.89 ± 14.91 2.929 (1.616 to 5.311)d 0b
aChi-square test for categorical variables, data was expressed as n (%); bStudent’s t-test for normally distributed continuous variables, data was expressed as
mean ± SD; cMann-Whitney U test for non-normally distributed continuous variables, data was expressed as median (IQR); dThe numbers of nucleus NF-κB
p65-positive cells were stratified by 10, and OR (95% CI) was calculated according to the binary logistic regression analysis.
Figure 1 The microscopic images of NF-κB p65 detected with IHC. Microscopic images (400×) showed that NF-κB p65 expressed in nucleus of
neurons and glial cells. (a) HE staining. (b) NF-κB p65 detected with IHC. (c) NF-κB p65/NSE double-labeled IHC. (d) NF-κB p65/GFAP double-labeled
IHC. 1→ indicates nucleus NF-κB p65-positive neurons or glial cells, 2→ indicates nucleus NF-κB p65-positive neurons, 3→ indicates nucleus NF-κB
p65-negative neurons, 4→ indicates nucleus NF-κB p65-positive glial cells, and 5→ indicates nucleus NF-κB p65-negative glial cells. HE, hematoxylin
and eosin; NF-κB, nuclear factor-κB; NSE, neuron-specific enolase; GFAP, glial fibrillary acidic protein.
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pneumonia (P = 0.002). There was no significant differ-
ence in sex, age, all of the researched risk factors, brain
edema, or hydrocephalus on admission. Then, the num-
bers of nucleus NF-κB p65-positive cells were stratified by
10, and the result was 1 case for 0~, 2 for 10 ~ and 20~, 8
for 30~, 5 for 40~, 6 for 50~, 8 for 60 ~ and 70~, 3 for
80~, and 2 for 90~. According to the binary logistic re-
gression analysis, β value was 1.075, OR was 2.929, and
the 95% CI was 1.616 to 5.311 (Table 1).
In the multivariate analysis, the variable entrance cut-
off was set as 0.10 according to the results of univariate
analysis. Therefore, GCS score on admission, hematoma
volume, intraventricular extension, midline shift, and
NF-κB activation were selected for multivariate analysis
using logistic regression. With stepwise logistic regres-
sion, NF-κB activation was the only independent pre-
dictor of the 6-month outcome. The prognostic accuracy
of NF-κB activation was assessed with ROC curve ana-
lysis. The area under curve (AUC) of NF-κB activation
was 0.893 (95% CI 0.787 to 0.999), which was higher
than that of GCS score on admission (0.748, 95% CI
0.590 to 0.906), hematoma volume (0.744, 95% CI 0.598
to 0.890), and midline shift (0.713, 95% CI 0.556 to
0.870) (Figure 2).
Relationship between baseline data and NF-κB activation
The relationship between every baseline data and NF-κB
activation was analyzed. Continuous variables were ana-
lyzed with binary linear regression, and categorical vari-
ables were analyzed with one-way ANOVA. The results
showed that NF-κB activation was significantly relatedFigure 2 The ROC curve of predictors to predict the poor clinical
outcome. The AUC of NF-κB activation, GCS score on admission,
hematoma volume, and midline shift were 0.893 (95% CI 0.787
to 0.999), 0.748 (95% CI 0.590 to 0.906), 0.744 (95% CI 0.598 to
0.890), and 0.713 (95% CI 0.556 to 0.870), respectively. NF-κB,
nuclear factor-κB; GCS, Glasgow Coma Scale.to GCS score on admission (P < 0.0001), hematoma vol-
ume (P < 0.0001), and midline shift (P = 0.006) and not
significantly related to sex, age, risk factors, or radiologic
variables except midline shift.
Discussion
The present study examines the relationships among clin-
ical data, NF-κB activation, and the 6-month outcome fol-
lowing primary ICH and produces the following major
findings. First, in univariate analysis, GCS score on admis-
sion, hematoma volume, intraventricular extension, mid-
line shift, mechanical ventilation, pneumonia, and NF-κB
activation were predictors of the 6-month functional out-
come. Second, in multivariate analysis, only NF-κB activa-
tion was independently associated with the 6-month
outcome. Third, on the linear regression analysis, NF-κB
activation was closely related to GCS score on admission,
hematoma volume, and midline shift.
In this study, GCS score on admission, hematoma vol-
ume, intraventricular extension, and midline shift were
predictors of the 6-month outcome, and this was con-
sistent with the literature [5-11]. But one thing should
be noted is that preoperative brain edema was not related
to the 6-month outcome according to the univariate ana-
lysis. The reason for this may be that the CT scanning
was performed within 10 h after onset of ICH, when the
edema just begun and had not reached the peak.
It is interesting that this study first newly identified
NF-κB activation as the only independent factor to predict
the poor clinical outcome after ICH according to the
multivariate analysis. This is mainly because that NF-κB
activation is affected by many baseline factors. In the lin-
ear regression analysis, NF-κB activation was closed re-
lated to GCS score on admission, hematoma volume, and
midline shift. Therefore, NF-κB activation might be af-
fected by the combined effect of the three factors and then
became the only independent factor.
The close relationship between NF-κB activation and
the 6-month outcome is probably due to the function of
NF-κB’s downstream factors. NF-κB is a ubiquitous tran-
scription factor and a member of a family of proteins
which are critical regulators of a variety of responses, in-
cluding inflammation [19]. In unstimulated cells, inactive
NF-κB is sequestered in the cytoplasm by inhibitory pro-
tein IκB, which prevents its translocation to the nucleus.
In response to various external pathogenic stimuli, includ-
ing thrombin, TNF-α, IL-1β, oxidative stress, growth fac-
tors, and so on [16,20,21], specific kinases phosphorylate
IκB, leading to its proteolysis and dissociation from
NF-κB. The free, newly activated NF-κB migrates into
the cell nucleus, where it binds to specific NF-κB re-
sponse elements in the promoters of target genes. This
promotes the transcription of genes for the release of
series of inflammatory substances, such as TNF-α, IL-1β,
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sion molecule-1 (ICAM-1), and so on. These substances
are closely related to the secondary neuronal injuries after
ICH, including blood–brain barrier disruption, brain
edema, and neuronal cell death [22-29], which lead to
poor functional outcome.
The results of this study have two major significances
for the treatment of ICH in the future. First, based on
these results, NF-κB activation in the perihematomal tis-
sue is closely related to the outcome of ICH patients, so
it can be detected to predict the prognosis of ICH accur-
ately. Second and more importantly, these findings offer
a potential therapeutic target for patients with ICH. It
might be possible to improve the outcome of ICH pa-
tients by interfering NF-κB activation. Studies on animal
ICH model have confirmed that some measures, such as
application of 6-O-acetyl shanzhiside methyl ester, taur-
oursodeoxycholic acid in 2 h after ICH, and neural stem
cell transplantation, could reduce the NF-κB activation
[30-32]. Therefore, these measures might be taken to
treat human ICH after clinical trials in the future.
There are several limitations in the current study that
should be addressed. On one hand, the sample size of
this study was relatively small and the patients enrolled
were relatively serious, because the brain tissue could
only be collected from patients with poor grades, who
needed surgery to evacuate the hematoma. The result of
this study may not be representative for all ICH patients.
Therefore, we will continue collecting more cases in
order to obtain a more convincible result. On the other
hand, although NF-κB activation in the perihematomal
tissue is closely related to the outcome of ICH patients,
it is still questionable whether NF-κB activation directly
leads to poor functional outcome or NF-κB activation is
just a compensatory mechanism to protect the brain tis-
sue from damage. In other words, promoting or inhibiting
NF-κB activation to improve the outcome of ICH patients
is still unclear. To clarify this issue, we will study the ICH
rat model, using gene overexpression, RNA interference,
and specific inhibition technology to interfere NF-κB acti-
vation at the different stages after ICH, detect the cell
death, observe the behavioral changes of rats, and finally
clarify the effect of NF-κB activation to the cell death and
outcome in different stages. Then, different measures can
be performed in different stages to improve the outcome
of ICH.
Conclusion
In summary, in the current study, we found that NF-κB
activation was closely related to the 6-month clinical
outcome after primary ICH in humans. Therefore, it can
be detected to predict the prognosis of ICH accurately.
Furthermore, these findings offer a potential therapeutic
target for patients with ICH. It might be possible toimprove the outcome of ICH patients by interfering NF-
κB activation in the future.
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